Heidelberg, Baden-Württemberg, Germany
I am an Assistant Professor of Technological Innovation and Management Science at the University of Mannheim, as well as a Research Fellow at the Leibniz Centre for European Economic Research. My research focuses on how incentives influence scientific discovery and its application. Drawing on my training in economics at Imperial, Oxford and WHU, as well as in public health at Yale and LSHTM, I collaborate internationally and serve on scientific advisory boards. I previously worked at the Boston Consulting Group in New York and co-founded InoCard, a gene therapy start-up that was acquired by uniQure in 2014 and partnered with Bristol Myers Squibb. I am currently building AaviGen, my second co-founded venture in gene therapy.
The Assistant Professorship (W1) conducts research into the economics, management, and policy of technological innovation and science more broadly. I currently teach graduate courses related to the conduct of scientific research at the Master and PhD level.
AaviGen GmbH is a biotechnology start-up. The company's primary purpose is the development and commercialization of precision gene therapies for cardiovascular and cardiopulmonary diseases. AaviGen's business model builds on the success of the InoCard GmbH, a predecessor that was sold to uniQure N.V. and subsequently entered into a development alliance with Bristol-Myers-Squibb.
Assisted the Commission as part of an expert group with advice on science policy
As part of my fellowship, I pursued research in the economics of innovation as well as the policy and management of science and technology. I also served as a guest lecturer in Yale's Executive MBA program on the topic of "Innovating in the pharmaceutical industry".